Browse the corpus

Flecainide acetate is a potent Class Ic antiarrhythmic agent used to manage supraventricular and select ventricular arrhythmias. Approved by the US Food and Drug Administration in 1984, flecainide plays a key role in rhythm control therapy for atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia in patients without structural heart disease. By blocking fast sodium channels, flecainide slows cardiac conduction and stabilizes myocardial electrical activity. Despite its effectiveness, inappropriate use may lead to proarrhythmic effects, underscoring the importance of careful patient selection, close monitoring, and adherence to evidence-based guidelines. This activity reviews the pharmacology, therapeutic applications, contraindications, and supporting clinical evidence for flecainide, including findings from the CAST and PITAGORA trials. The discussion includes dosing strategies, monitoring parameters, toxicity management, and the role of the interprofessional care team in ensuring safe and effective therapy. Participation in this activity equips clinicians with the knowledge and practical tools needed to optimize arrhythmia management and improve patient outcomes. Objectives: Evaluate patient eligibility for flecainide therapy based on structural heart status, comorbidities, and guideline recommendations. Assess early signs of flecainide toxicity and intervene appropriately to prevent adverse cardiac events. Develop individualized care plans integrating pharmacologic therapy, patient education, and follow-up for arrhythmia management. Strategize interprofessional interventions to optimize rhythm control and minimize proarrhythmic risk in patients receiving flecainide. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose There is no specific antidote for flecainide overdose. Ingestion of doses up to 8000 mg has been survived, with reported plasma concentrations as high as 5.3 mcg/mL. Clinical features may include nausea, vomiting, seizures, hypotension, bradycardia, syncope, and pronounced ECG abnormalities such as marked QRS widening, QT and PR prolongation, ventricular tachycardia, atrioventricular block, asystole, bundle branch block, heart failure, or cardiac arrest. Fatal outcomes have occurred following ingestion of as little as 1000 mg, often in the context of co-ingestion with other medications or alcohol. Flecainide plasma levels should be obtained to confirm toxicity. The therapeutic window for flecainide is narrow, ranging from 0.2 to 1.0 mcg/mL.[30] A patient with atrial tachyarrhythmia and pacemaker therapy developed a wide-QRS tachycardia that mimicked ventricular tachycardia. Pacemaker interrogation confirmed atrial flutter with pacemaker-mediated ventricular pacing, consistent with flecainide toxicity.[31][32] Infrequent cases of suicide by intentional flecainide overdose have been reported in the literature.[33][34][35] Management of Overdose Management of an overdose is mainly supportive, and there is no antidote for flecainide overdose. According to the review of literature, the documented mortality rate from overdose of Class Ic Vaughan Williams antiarrhythmics stands at 22.5%. Standard treatments include aggressive fluid resuscitation, administration of hypertonic sodium bicarbonate, and intravenous magnesium.[36] The initial management of toxicity involves administering a sodium bicarbonate infusion to promptly counteract the effects of flecainide, thereby preventing potentially life-threatening arrhythmias. Case reports indicate that sodium bicarbonate can be used as monotherapy and is commonly given as first-line treatment for a QRS duration of greater than 100 ms, in increments of 1 to 2 mEq/kg. Sodium bicarbonate raises serum pH and increases extracellular sodium levels, enabling it to compete with flecainide for sodium channel binding and strengthening the electrochemical gradient across cell membranes.[37] Consult a medical toxicologist and contact the national poison control center for up-to-date information.

Management of an overdose is mainly supportive, and there is no antidote for flecainide overdose. According to the review of literature, the documented mortality rate from overdose of Class Ic Vaughan Williams antiarrhythmics stands at 22.5%. Standard treatments include aggressive fluid resuscitation, administration of hypertonic sodium bicarbonate, and intravenous magnesium.[36] The initial management of toxicity involves administering a sodium bicarbonate infusion to promptly counteract the effects of flecainide, thereby preventing potentially life-threatening arrhythmias. Case reports indicate that sodium bicarbonate can be used as monotherapy and is commonly given as first-line treatment for a QRS duration of greater than 100 ms, in increments of 1 to 2 mEq/kg. Sodium bicarbonate raises serum pH and increases extracellular sodium levels, enabling it to compete with flecainide for sodium channel binding and strengthening the electrochemical gradient across cell membranes.[37] Consult a medical toxicologist and contact the national poison control center for up-to-date information. Lipid emulsion therapy can also be used in conjunction with sodium bicarbonate for flecainide toxicity. The "lipid sink" theory suggests that it removes lipophilic flecainide from toxicity sites by increasing blood lipid levels.[38] Management is mainly supportive. Prompt gastrointestinal decontamination should be considered to limit absorption. Hemodynamic instability may respond to inotropic or chronotropic agents. Mechanical ventilation may be required in patients with severe cardiac and respiratory depression. Advanced supportive measures, including intra-aortic balloon counterpulsation or transvenous pacing, may be indicated in cases of refractory conduction block or profound hemodynamic compromise.[39] Due to flecainide's prolonged elimination half-life (approximately 12–27 hours) and potential for nonlinear kinetics at toxic concentrations, extended monitoring and supportive care are essential. Hemodialysis does not enhance clearance.

This section discusses the evidence-based use and outcomes of flecainide across various clinical settings. CAST Trial Initially, it was thought to be effective in the treatment of premature ventricular contractions and nonsustained ventricular tachycardia after myocardial infarction to reduce the incidence of sudden death. However, in a multicenter randomized placebo-controlled trial on patients after myocardial infarction, the use of flecainide was associated with increased mortality due to fatal arrhythmias. Therefore, flecainide is considered for patients without coronary artery disease and left ventricular dysfunction. Currently, contraindications to flecainide include patients with left ventricular hypertrophy, ischemic heart disease, hypertrophic obstructive cardiomyopathy, high-degree atrioventricular block, and complete heart block.[40] PITAGORA Trial A multicenter, single-blind, prospective randomized trial compared amiodarone with Class Ic (propafenone and flecainide) in patients with atrial fibrillation and a pacemaker due to sinus node disease for maintaining sinus rhythm as a goal. Flecainide was found to be noninferior and equally efficacious in preventing episodes lasting more than 10 minutes or those lasting for 1 day.[41] Pill-in-the-Pocket Approach According to the NEJM study published in 2004, flecainide is one of the drugs, apart from propafenone, used in outpatient or emergency department settings to treat symptomatic atrial fibrillation. In some patients, oral prophylaxis or catheter ablation may not be feasible; therefore, a single dose of an antiarrhythmic medication at the time of symptom onset is an appropriate option. The dose of flecainide was 300 mg for patients of more than 70 kg or 200 mg otherwise. Around 165 patients were followed for 2 years; 94% were successfully treated after the onset of symptoms within 2 hours. Recurrences were successfully treated in up to 84% of cases. The number of emergency room visits and hospitalizations was significantly lower during the study period compared to the year before the treatment period.[42] Acute Cardioversion in Emergency Departments

According to the NEJM study published in 2004, flecainide is one of the drugs, apart from propafenone, used in outpatient or emergency department settings to treat symptomatic atrial fibrillation. In some patients, oral prophylaxis or catheter ablation may not be feasible; therefore, a single dose of an antiarrhythmic medication at the time of symptom onset is an appropriate option. The dose of flecainide was 300 mg for patients of more than 70 kg or 200 mg otherwise. Around 165 patients were followed for 2 years; 94% were successfully treated after the onset of symptoms within 2 hours. Recurrences were successfully treated in up to 84% of cases. The number of emergency room visits and hospitalizations was significantly lower during the study period compared to the year before the treatment period.[42] Acute Cardioversion in Emergency Departments Based on recent meta-analyses, IV flecainide is superior to other antiarrhythmics, such as ibutilide, amiodarone, sotalol, propafenone, and procainamide. Eleven randomized controlled trials were analyzed, and it was found that flecainide was highly effective for cardioversion within 2 hours. There is no statistically significant difference in proarrhythmic behavior compared to placebo or other antiarrhythmics.[43] Effect on Atrial Remodeling Structural changes in the atria occur due to atrial fibrillation, leading to myocardial remodeling and mitochondrial dysfunction caused by oxidative stress. During atrial fibrillation, atrial activation rapidly leads to intracellular calcium accumulation via the Na+/Ca2+ exchanger. Flecainide inhibits intracellular Ca2+ accumulation, which reduces atrial remodeling and oxidative stress.[44] Fetal Tachycardia Flecainide has been shown to be effective in the transplacental treatment of fetal tachycardia. Flecainide was found to be superior to digoxin and sotalol in the termination of fetal tachycardia, especially supraventricular tachycardia. The placental transfer is not affected in hydrops fetalis.[45] Catecholaminergic Polymorphic Ventricular Tachycardia

Flecainide has been shown to be effective in the transplacental treatment of fetal tachycardia. Flecainide was found to be superior to digoxin and sotalol in the termination of fetal tachycardia, especially supraventricular tachycardia. The placental transfer is not affected in hydrops fetalis.[45] Catecholaminergic Polymorphic Ventricular Tachycardia As discussed above, flecainide inhibits cardiac ryanodine receptors in their open state, which are responsible for calcium release and lead to CPVT. Flecainide suppresses 76% of exercise-induced ventricular arrhythmias in 33 genotype-positive patients. It is also efficacious in suppressing ventricular tachyarrhythmias in genotype-negative patients.[46] Practical Aspects Before and During Initiation of Flecainide An exercise stress test should be performed before initiating flecainide therapy to rule out coronary artery disease and repeated during treatment if resting QRS prolongation is observed. ECG monitoring is recommended to assess QRS duration. The flecainide dose should be reduced to half the initial dose if the QRS duration increases by 25%. Patients should be screened for sinus node dysfunction and atrioventricular node disease prior to treatment initiation. Concurrent administration of negative chronotropic agents, such as beta-blockers, is recommended. While pharmaceutical therapy with flecainide should be initiated only by a cardiologist, it requires an interprofessional team approach, including the patient, other clinicians and specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient outcomes. As a narrow therapeutic index medication, all healthcare team members must be aware of the patient's therapy, recognize signs of toxicity or inadequate response, and communicate openly with other interprofessional team members regarding treatment progress and adverse events to optimize therapeutic outcomes and improve the patient's condition.